Evidence map›Paper›PMID 36129295›Full record

ArticleAntimicrobial agents and chemotherapy2022

Functional and Structural Characterization of OXA-935, a Novel OXA-10-Family β-Lactamase from Pseudomonas aeruginosa.

Nathan B Pincus, Monica Rosas-Lemus, Samuel W M Gatesy, Hanna K Bertucci, Joseph S Brunzelle, George Minasov, Ludmilla A Shuvalova, Marine Lebrun-Corbin, Karla J F Satchell, Egon A Ozer and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Mechanisms involved in cefiderocol resistance in FrenchAntimicrobial agents and chemotherapy · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Nathan B Pincus *Department of Microbiology-Immunology, Northwestern Universitygrid.16753.36, Feinberg School of Medicine, Chicago, Illinois, USA.
Monica Rosas-Lemus *Department of Microbiology-Immunology, Northwestern Universitygrid.16753.36, Feinberg School of Medicine, Chicago, Illinois, USA.
Samuel W M GatesyDepartment of Medicine, Division of Infectious Diseases, Northwestern Universitygrid.16753.36, Feinberg School of Medicine, Chicago, Illinois, USA.
Hanna K BertucciDepartment of Medicine, Division of Infectious Diseases, Northwestern Universitygrid.16753.36, Feinberg School of Medicine, Chicago, Illinois, USA.
Joseph S BrunzelleNorthwestern Synchrotron Research Center, Life Sciences Collaborative Access Team, Northwestern Universitygrid.16753.36, Argonne, Illinois, USA.
George MinasovDepartment of Microbiology-Immunology, Northwestern Universitygrid.16753.36, Feinberg School of Medicine, Chicago, Illinois, USA.
Ludmilla A ShuvalovaDepartment of Microbiology-Immunology, Northwestern Universitygrid.16753.36, Feinberg School of Medicine, Chicago, Illinois, USA.
Marine Lebrun-CorbinDepartment of Microbiology-Immunology, Northwestern Universitygrid.16753.36, Feinberg School of Medicine, Chicago, Illinois, USA.
Karla J F SatchellDepartment of Microbiology-Immunology, Northwestern Universitygrid.16753.36, Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0003-3274-7611
Egon A OzerDepartment of Medicine, Division of Infectious Diseases, Northwestern Universitygrid.16753.36, Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0002-7131-3691
Alan R Hauser *Department of Microbiology-Immunology, Northwestern Universitygrid.16753.36, Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0003-4596-7939
Kelly E R Bachta *Department of Microbiology-Immunology, Northwestern Universitygrid.16753.36, Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0001-8838-5117
Northwestern University · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1993 to 2026
$153.9M
Unfolded Protein Response and Autophagy in T Helper Cell Effector FunctionP20GM121176 · NIGMS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Monica Rosas Lemus · 2017 to 2026
$24.9M
Technology CoreU19AI135964 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI JUSTIN B. STARREN · 2018 to 2026
$24.7M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008152 · NIGMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ARDEHALI, HOSSEIN · 1987 to 2021
$24.0M
CELLULAR &MOLECULAR BASIS OF DISEASE TRAINING PROGRAMT32GM008061 · NIGMS · NORTHWESTERN UNIVERSITY · PI CARTHEW, RICHARD W. · 1985 to 2022
$17.1M
Systems Biology Approach to Redefine Susceptibility Testing and Treatment of MDR Pathogens in the Context of Host ImmunityU01AI124316 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PALSSON, BERNHARD O · 2016 to 2020
$10.2M
Population Analysis of Pseudomonas aeruginosa VirulenceR01AI118257 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2016 to 2025
$4.9M
Mechanistic Studies of Patatin-like ToxinsR01AI053674 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2003 to 2017
$4.3M
Understanding structural flexibility and evolutionary divergence of proteinsR35GM118187 · NIGMS · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI GODZIK, ADAM · 2016 to 2020
$1.9M
Biomarkers for Highly Virulent Pseudomonas aeruginosa StrainsR21AI129167 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2017 to 2018
$570k
HHS | NIH | National Cancer Institute (NCI) NCI CCSG P30 CA060553HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) HHSN272017000060CHHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) RO1 AI118257HHS | NIH | National Institute of General Medical Sciences (NIGMS) GM118187NCI NIH HHS P30 CA060553NIAID NIH HHS R01 AI053674NIAID NIH HHS R01 AI118257NIAID NIH HHS R21 AI129167NIAID NIH HHS U01 AI124316NIAID NIH HHS U19 AI135964NIGMS NIH HHS P20 GM121176NIGMS NIH HHS R35 GM118187NIGMS NIH HHS T32 GM008061NIGMS NIH HHS T32 GM008152
6 · The paper itself

Abstract

Resistance to antipseudomonal penicillins and cephalosporins is often driven by the overproduction of the intrinsic β-lactamase AmpC. However, OXA-10-family β-lactamases are a rich source of resistance in Pseudomonas aeruginosa. OXA β-lactamases have a propensity for mutation that leads to extended spectrum cephalosporinase and carbapenemase activity. In this study, we identified isolates from a subclade of the multidrug-resistant (MDR) high risk P. aeruginosa clonal complex CC446 with a resistance to ceftazidime. A genomic analysis revealed that these isolates harbored a plasmid containing a novel allele of

Indexed as

CeftazidimePseudomonas InfectionsAnti-Bacterial AgentsAspartic AcidAzabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-LactamasesCephalosporinaseCephalosporinsGlycineHumansMicrobial Sensitivity TestsPhenylalaninePseudomonas aeruginosaSerineTazobactamAnti-Bacterial AgentsAspartic AcidAzabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-lactamase PSE-2beta-LactamasesCeftazidimeCephalosporinaseCephalosporinsGlycinePhenylalanineSerineTazobactamantimicrobial resistanceceftazidimecrystal structureOXA-β-lactamasePseudomonas aeruginosa

Identifiers

PMID36129295
PMCPMC9578422
OpenAlexW4296706649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.